^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    afimoxifene

    Company:
    Besins Healthcare
    Drug class:
    Selective estrogen receptor modulator
    Related drugs:
    2ms
    Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast (clinicaltrials.gov)
    P2, N=156, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jan 2024 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    tamoxifen • afimoxifene
    12ms
    Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast (clinicaltrials.gov)
    P2, N=100, Completed, Northwestern University | Recruiting --> Completed | Phase classification: P2b --> P2
    Trial completion • Phase classification
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    afimoxifene • Soltamox (tamoxifen citrate)
    almost2years
    Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov)
    P2, N=194, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    tamoxifen • afimoxifene
    over2years
    Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov)
    P2, N=194, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2023 --> Oct 2023 | Trial primary completion date: Apr 2023 --> Oct 2023
    Trial completion date • Trial primary completion date
    |
    AURKA (Aurora kinase A) • CD68 (CD68 Molecule)
    |
    tamoxifen • afimoxifene
    almost3years
    Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov)
    P2, N=194, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Oct 2021 --> Apr 2023
    Trial primary completion date
    |
    AURKA (Aurora kinase A) • CD68 (CD68 Molecule)
    |
    tamoxifen • afimoxifene
    over3years
    Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov)
    P2, N=152, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Apr 2023 --> Oct 2021
    Trial primary completion date
    |
    AURKA (Aurora kinase A) • CD68 (CD68 Molecule)
    |
    tamoxifen • afimoxifene
    over3years
    Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov)
    P2, N=152, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2021 --> Apr 2023 | Trial primary completion date: Oct 2021 --> Apr 2023
    Trial completion date • Trial primary completion date
    |
    AURKA (Aurora kinase A) • CD68 (CD68 Molecule)
    |
    tamoxifen • afimoxifene
    over3years
    Evaluation of human adipose-derived stromal cell behaviour following exposure to Tamoxifen. (PubMed, Tissue Cell)
    At physiologically relevant doses, Tamoxifen treatment did not result in any deleterious effect on ASC survival and functionality and is unlikely to negatively impact ASC based breast reconstruction strategies for breast cancer patients receiving this adjuvant hormonal therapy.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER expression
    |
    afimoxifene
    4years
    Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov)
    P2, N=152, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Oct 2021
    Clinical • Enrollment closed • Trial completion date
    |
    AURKA (Aurora kinase A) • CD68 (CD68 Molecule)
    |
    tamoxifen • afimoxifene
    almost5years
    Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov)
    P2, N=152, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Sep 2020 --> Sep 2022 | Trial primary completion date: Sep 2020 --> Sep 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    AURKA (Aurora kinase A) • CD68 (CD68 Molecule)
    |
    tamoxifen • afimoxifene
    almost6years
    Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast (clinicaltrials.gov)
    P2b; Trial completion date: Jul 2019 --> Jul 2023 | Trial primary completion date: Jul 2019 --> Jul 2022
    Trial completion date • Trial primary completion date • Clinical
    |
    ER (Estrogen receptor) • IGF1 (Insulin-like growth factor 1) • CD68 (CD68 Molecule)
    |
    ER positive
    |
    Oncotype DX Breast DCIS Score test
    |
    afimoxifene • Soltamox (tamoxifen citrate)
    over8years
    Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast (clinicaltrials.gov)
    P2b; Not yet recruiting --> Recruiting
    Enrollment open • Clinical
    |
    ER (Estrogen receptor) • IGF1 (Insulin-like growth factor 1) • CD68 (CD68 Molecule)
    |
    ER positive
    |
    Oncotype DX Breast DCIS Score test
    |
    afimoxifene • Soltamox (tamoxifen citrate)